[{"id":"5cc7e0ed-f106-4a96-bfa9-c63f255c96f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06850506","created_at":"2025-03-03T10:01:05.906Z","updated_at":"2025-03-03T10:01:05.906Z","phase":"","brief_title":"Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment","source_id_and_acronym":"NCT06850506","lead_sponsor":"Peking University People's Hospital","biomarkers":" CDH6","pipe":"","alterations":" ","tags":["CDH6"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-27"},{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"c3ccbe27-3d9e-4190-a952-e531da2607f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890093","created_at":"2021-05-18T12:01:54.563Z","updated_at":"2025-02-25T13:49:09.588Z","phase":"Phase 1/2","brief_title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT04890093","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-20"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"9a0a8faa-2764-48be-bddc-53cde9f97223","acronym":"LiFFT","url":"https://clinicaltrials.gov/study/NCT05918640","created_at":"2023-06-26T14:09:13.345Z","updated_at":"2025-02-25T15:13:34.219Z","phase":"Phase 1/2","brief_title":"Lurbinectedin in FET-Fused Tumors","source_id_and_acronym":"NCT05918640 - LiFFT","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4","pipe":"","alterations":" ","tags":["EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zepzelca (lurbinectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-13"},{"id":"7114fae7-0419-4c0e-a010-ae5f4d1c710b","acronym":"AEWS1221","url":"https://clinicaltrials.gov/study/NCT02306161","created_at":"2023-11-28T02:14:27.984Z","updated_at":"2025-02-25T16:36:29.981Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","source_id_and_acronym":"NCT02306161 - AEWS1221","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • daunorubicin • ganitumab (AMG 479)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 09/19/2025","study_completion_date":" 09/19/2025","last_update_posted":"2025-02-06"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"0811eebd-2541-4c17-9f6e-9259710f1407","acronym":"TARGET-RT","url":"https://clinicaltrials.gov/study/NCT06796543","created_at":"2025-02-25T16:28:16.453Z","updated_at":"2025-02-25T16:28:16.453Z","phase":"","brief_title":"Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma","source_id_and_acronym":"NCT06796543 - TARGET-RT","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EFS","pipe":"","alterations":" ","tags":["EFS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-29"},{"id":"c515fc0a-eb3f-4509-a7dc-e23a2f9595b0","acronym":"REGO-EWING","url":"https://clinicaltrials.gov/study/NCT05830084","created_at":"2023-04-26T14:04:47.284Z","updated_at":"2025-02-25T17:26:10.222Z","phase":"Phase 1","brief_title":"Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma","source_id_and_acronym":"NCT05830084 - REGO-EWING","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" EWSR1","pipe":"","alterations":" ","tags":["EWSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/16/2023","start_date":" 06/16/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-11-28"},{"id":"d9dd8a9e-c9dc-461e-aece-5bc7f49d536e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03709680","created_at":"2021-11-09T18:05:08.609Z","updated_at":"2024-07-02T16:35:02.132Z","phase":"Phase 1/2","brief_title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","source_id_and_acronym":"NCT03709680","lead_sponsor":"Pfizer","biomarkers":" EWSR1 • FUS","pipe":"","alterations":" ","tags":["EWSR1 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • temozolomide • cyclophosphamide • irinotecan • topotecan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 05/24/2019","start_date":" 05/24/2019","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2024-05-22"},{"id":"1ba7d423-e8de-4bf4-9f12-f7ec8c7c5db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03526250","created_at":"2021-01-18T17:22:05.437Z","updated_at":"2024-07-02T16:35:02.332Z","phase":"Phase 2","brief_title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03526250","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-21"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"82dcc018-99ce-47f7-8c3b-045c9ebf3e1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220035","created_at":"2021-01-18T15:53:33.764Z","updated_at":"2024-07-02T16:35:02.750Z","phase":"Phase 2","brief_title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03220035","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-17"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"27578ddc-f283-4d0d-bcd4-108743a5b2fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530487","created_at":"2021-01-18T21:41:28.381Z","updated_at":"2024-07-02T16:35:10.209Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","source_id_and_acronym":"NCT04530487","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 05/09/2025","primary_completion_date":" 05/09/2025","study_txt":" Completion: 05/09/2025","study_completion_date":" 05/09/2025","last_update_posted":"2024-04-11"},{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"fca0acc3-ee52-4102-a447-7fd22d0a32ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT02162732","created_at":"2021-01-18T10:04:10.523Z","updated_at":"2024-07-02T16:35:11.152Z","phase":"","brief_title":"Molecular-Guided Therapy for Childhood Cancer","source_id_and_acronym":"NCT02162732","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 01/18/2024","primary_completion_date":" 01/18/2024","study_txt":" Completion: 01/18/2024","study_completion_date":" 01/18/2024","last_update_posted":"2024-04-05"},{"id":"1079f78e-9ce0-445a-837c-c2dc7bc96947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05275426","created_at":"2022-03-11T15:53:40.436Z","updated_at":"2024-07-02T16:35:13.985Z","phase":"Phase 2","brief_title":"A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor","source_id_and_acronym":"NCT05275426","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4","pipe":" | ","alterations":" EWSR1-WT1 fusion","tags":["WT1 • BCOR • EWSR1 • ETV1 • FLI1 • ETV4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EWSR1-WT1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • ESP-01"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/02/2022","start_date":" 03/02/2022","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2025","study_completion_date":" 03/02/2025","last_update_posted":"2024-03-19"},{"id":"ffe96379-a55d-4c21-b2bf-0bb984a6f16f","acronym":"STIR Trial","url":"https://clinicaltrials.gov/study/NCT02100891","created_at":"2021-01-18T09:42:21.170Z","updated_at":"2024-07-02T16:35:15.156Z","phase":"Phase 2","brief_title":"Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors","source_id_and_acronym":"NCT02100891 - STIR Trial","lead_sponsor":"Monica Thakar","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 03/20/2013","start_date":" 03/20/2013","primary_txt":" Primary completion: 06/08/2020","primary_completion_date":" 06/08/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2024-03-12"},{"id":"365bcd51-2ab8-4615-b16d-85cc815ed781","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505569","created_at":"2021-01-18T06:19:27.289Z","updated_at":"2025-02-25T14:00:01.019Z","phase":"","brief_title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","source_id_and_acronym":"NCT01505569","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYCN • CD34","pipe":" | ","alterations":" LDH elevation • MYCN expression","tags":["MYCN • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation • MYCN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 10/20/2011","start_date":" 10/20/2011","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-26"}]